LecicarbonLogo500

HEALTHCARE PROFESSIONALS

> Take me to the Patient area

Patient Info

Lecicarbon Prescribing information (please consult the SmPCs before prescribing)

Lecicarbon contains sodium dihydrogen carbonate (Lecicarbon A: 0.50g per suppository; Lecicarbon C: 0.25g per suppository) and sodium dihydrogen phosphate (Lecicarbon A: 0.68g per suppository; Lecicarbon C: 0.34g per suppository). Indications: Lecicarbon is used in all forms of frequent constipation (habitual or chronic), especially where the rectal emptying reflex is weak; constipation due to low-fibre food or insufficient exercise (bedridden patients); to evacuate the bowel prior to surgery or diagnostic procedures (e.g. x-rays, rectoscopy and before childbirth); can be used in addition to other laxatives if they have been proven to be ineffective. Contraindications: Lecicarbon should not be used in cases of ileus (intestinal obstruction), in case of all anal and rectal region diseases that can lead to an excessive absorption of carbon dioxide, especially in children and infants, and in the case of hypersensitivity to soya, peanut or one of the excipients of Lecicarbon suppository. In the presence of toxic megacolon, the product should only be used with explicit permission of the treating physician. Side effects: Rarely Soya lecithin has been known to cause allergic reactions. The insertion of the suppository can very occasionally cause a slight burning sensation, which quickly disappears. Dosage and method of use: Insert one suppository into the rectum, if needed this can be repeated after 30-60 minutes. MA number: Lecicarbon A: PL 28418/0001; Lecicarbon C: PL 28418/0002. Cost: £8.20. MAH: athenstaedt GmbH & Co KG, Am Beerberg 1, 35088 Battenberg, Germany. Distributed by: Aspire Pharma Ltd, Bellamy House, Winton Road, Petersfield, Hampshire, GU32 3HA. Legal category: P. Date last reviewed: March 2015.

For further information, please call: 01730 231148, email: info@aspirepharma.co.uk
or visit www.aspirepharma.co.uk

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Lecicarbon, please see full prescribing information.
Revision date 19 June 2015